IRINOTECAN INTAS irinotecan hydrochloride trihydrate 300 mg/15 mL concentrated injection vial

Χώρα: Αυστραλία

Γλώσσα: Αγγλικά

Πηγή: Department of Health (Therapeutic Goods Administration)

Δραστική ουσία:

irinotecan hydrochloride trihydrate, Quantity: 300 mg

Διαθέσιμο από:

Accord Healthcare Pty Ltd

Φαρμακοτεχνική μορφή:

Injection, concentrated

Σύνθεση:

Excipient Ingredients: hydrochloric acid; sodium hydroxide; lactic acid; water for injections; sorbitol

Οδός χορήγησης:

Intravenous Infusion

Μονάδες σε πακέτο:

1

Τρόπος διάθεσης:

(S4) Prescription Only Medicine

Θεραπευτικές ενδείξεις:

Irinotecan hydrochloride is indicated as a component of first-line therapy for patients with metastatic carcinoma of the colon or rectum. Irinotecan hydrochloride is also indicated for patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial therapy.

Περίληψη προϊόντος:

Visual Identification: A pale yellow clear solution; Container Type: Vial; Container Material: Glass Type I Coloured; Container Life Time: 36 Months; Container Temperature: Store below 25 degrees Celsius

Καθεστώς αδειοδότησης:

Registered

Ημερομηνία της άδειας:

2020-03-05